|Articles|June 22, 2021

OneXpress™ Solution for Accelerating Development to Commercialisation

Author(s)Catalent

Catalent’s OneXpress™ solution combines phase-appropriate scale and technologies with expertise across diverse dose forms to simplify development and accelerate a programme towards commercialisation.

Catalent’s OneXpress is a single, integrated solution that provides the fastest pathway from clinical development to commercial manufacturing. By taking a proactive approach and assessing production considerations early in development, the solution can help reduce a programme’s risk and increase chances of success by working in parallel to address potential roadblocks and ensure robust processes from clinic to launch.

Using Catalent’s integrated global network of facilities, and streamlined programme management, the OneXpress solution combines the expertise at Catalent’s early-phase drug development centres of excellence in Nottingham, U.K., Somerset, New Jersey, and San Diego in the U.S., with the proven track-record of Catalent’s oral solid dose commercial manufacturing facilities.

Overseen by a dedicated programme manager from start to finish, OneXpress combines phase-appropriate technologies and proven expertise, with scalable end-to-end capabilities throughout an extensive supply network, to achieve optimal accelerated manufacturing solutions at every stage.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.